Skip to main content

Advertisement

SpringerLink
Log in

Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma

  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Combined hepatocellular-cholangiocarcinoma (CHC), also referred to as primary liver carcinoma (PLC) with biphenotypic differentiation, is an increasingly recognized subtype of malignant PLC encompassing varying morphologic forms thought to arise either from progenitor cell lineage or dedifferentiation of mature liver cells. Tumor cells express both biliary and hepatocellular markers by immunohistochemistry, and may also express progenitor cell and stem cell markers. Due to the relative rarity of this tumor type, little is known about the risk factors, imaging appearance, or prognosis. Few studies have demonstrated risk factors that overlap with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), though not all appear to arise in the background of cirrhosis. The imaging appearances of these tumors may overlap with those of HCC and CC and discriminating features such as classic enhancement patterns and biliary ductal dilation are not universally present. Serum tumor markers, such as alpha-fetoprotein and carbohydrate antigen 19-9, may be helpful when they are discordant with imaging or if both are elevated to a significant degree. In regards to management and prognosis, most studies demonstrate worse outcomes compared with HCC or CC. In the United States, the diagnosis of HCC is frequently made with imaging alone, and subsequent management decisions, including organ allocation for transplantation, rely upon the radiological diagnosis. Given the importance of radiological diagnosis, awareness of this tumor type is essential for appropriate management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Reference

  1. Jarnagin WR, Weber S, Tickoo SK, et al. (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94(7):6–2040

    Article  Google Scholar 

  2. Theise ND, Nakashima O, Park YN, Nakanuma Y (2010) Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) Who classification of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer, pp 225–227

    Google Scholar 

  3. Kassahun WT, Hauss J (2008) Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 62(8):8–1271

    Article  Google Scholar 

  4. Yu XH, Xu LB, Zeng H, et al. (2011) Clinicopathologic analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 10(6):5–620

    Article  Google Scholar 

  5. Coulouarn C, Cavard C, Rubbia-Brandt L, et al. (2012) Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis 33(9):6–1791

    Article  Google Scholar 

  6. Itoyama M, Hata M, Yamanegi K, et al. (2012) Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma. Med Mol Morphol 45(1):7–13

    Article  CAS  PubMed  Google Scholar 

  7. Al-Muhannadi N, Ansari N, Brahmi U, Satir AA (2011) Differential diagnosis of malignant epithelial tumours of the liver: an immunohistochemical study on liver biopsy. Ann Hepatol 10(4):508–515

    PubMed  Google Scholar 

  8. Lei JY, Bourne PA, DiSant’Agnese PA, Huang J (2006) Cystoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol 125(4):25–519

    Article  Google Scholar 

  9. Lefkowitch JH (ed) (2010) Neoplasms and nodules. In: Scheuer’s liver biopsy interpretation, 8th edn. London: Saunders Elsevier, pp 181–232

  10. Zhang F, Chen XP, Zhang W, et al. (2008) Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52(2):32–224

    Google Scholar 

  11. Wang J, Wang F, Kessinger A (2010) Outcome of combined hepatocellular and cholangiocarcinoma of the liver. J Oncol. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939443/. Accessed 1 Feb 2013

  12. Lee CH, Hsieh SY, Chang CJ, Lin YJ (2013) Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 28(1):7–122

    Article  Google Scholar 

  13. Yin X, Zhang BH, Qiu SJ, et al. (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19(9):76–2869

    Google Scholar 

  14. de Campos RO, Semelka RC, Azevedo RM, et al. (2012) Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging 36(5):47–1139

    Article  Google Scholar 

  15. Tang D, Nagano H, Nakamura M, et al. (2006) Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular carcinoma and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 10(7):98–987

    Google Scholar 

  16. Fowler KJ, Brown JJ, Narra VR (2011) Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology 54(6):37–2227

    Article  Google Scholar 

  17. Panjala C, Senecal DL, Bridges MD, et al. (2010) The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant 10(5):7–1263

    Article  Google Scholar 

  18. Hwang J, Kim YK, Park MJ, et al. (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36(4):9–881

    Article  Google Scholar 

  19. Ebied O, Federle MP, Blachar A, et al. (2003) Hepatocellular-cholangiocarcinoma: helical computed tomography findings in 30 patients. J Comput Assist Tomogr 27(2):24–117

    Google Scholar 

  20. Nishie A, Yoshimitsu K, Asayama Y, et al. (2005) Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR Am J Roentgenol 184(4):62–1157

    Article  Google Scholar 

  21. Koh KC, Lee H, Choi MS, et al. (2005) Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 189(1):5–120

    Article  Google Scholar 

  22. Liu CL, Fan ST, Lo CM, et al. (2003) Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg 138(1):86–90

    Article  PubMed  Google Scholar 

  23. Lee JH, Chung GE, Yu SJ, et al. (2011) Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison: comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 45(10):69–75

    PubMed  Google Scholar 

  24. Sapisochin G, Fidelman N, Roberts JP, Yao FY (2011) Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinomain patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 17(8):42–934

    Article  Google Scholar 

  25. Chi M, Mikhitarian K, Shi C, Goff LW (2012) Management of combined hepatocellular-cholangiocarcinoma. Gastrointest Cancer Res 5(6):199–202

    PubMed Central  PubMed  Google Scholar 

  26. Valle J, Wasan H, Palmer DH, et al. (2010) Cisplatin plus gemcitabine for biliary tract cancer. N Eng J Med 362(14):81–1273

    Article  Google Scholar 

  27. Chapman W, Tan BR, Doyle M, et al. Pilot study of hepatic arterial infusion in treating patients with locally advanced, non-metastatic cholangiocarcinoma. http://clinicaltrials.gov/ct2/show/record/NCT01525069. Accessed 16 Feb 2013

  28. Purysko AS, Remer EM, Coppa CP, et al. (2012) LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics 32(5):95–1977

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd, Campus Box 8131, Saint Louis, MO, 63110, USA

    Anup S. Shetty, Kathryn J. Fowler, Saurabh Agarwal, Vamsi R. Narra & Christine O. Menias

  2. Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, 63110, USA

    Elizabeth M. Brunt

Authors
  1. Anup S. Shetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn J. Fowler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth M. Brunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saurabh Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vamsi R. Narra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christine O. Menias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anup S. Shetty.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shetty, A.S., Fowler, K.J., Brunt, E.M. et al. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39, 310–322 (2014). https://doi.org/10.1007/s00261-013-0069-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-013-0069-6

Keywords

Search

Navigation